GNOSPV-01 is under clinical development by Geneos Therapeutics and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GNOSPV-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GNOSPV-01 overview
GNOSPV-01 is under investigation for the prevention of recurrent brain tumor, metastatic hormone-sensitive prostate cancer, glioblastoma multiforme, small-cell lung cancer, non-small cell lung cancer, and follicular lymphoma. Personalized peptide vaccination identifies the specific peptides that mark the tumor as dangerous and reintroduce them in increased concentration to the immune system via vaccination. It is administered through subcutaneous and intramuscular route. The vaccine candidate was also under development for renal cell carcinoma and pancreatic cancer.
It was also under development for the treatment of triple negative breast cancer.
Geneos Therapeutics overview
Geneos Therapeutics, is a biopharmaceutical company that develops neoantigen targeting cancer immunotherapies. The company is headquartered in United States.
For a complete picture of GNOSPV-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
